Abstract: The invention relates to an insulated building wall comprising a composite thermal insulation system and an external building wall, where the composite thermal insulation system is affixed to the side of the building wall facing away from the building, the composite thermal insulation system comprising an at least two-layer thermal insulation cladding, with at least two layers each containing from 25 to 95% by weight of aerogel and from 5 to 75% by weight of inorganic fibers and from 0 to 70% by weight of inorganic fillers, wherein the layers of the thermal insulation cladding are joined to one another by means of an inorganic binder and the composite thermal insulation system has a gross calorific potential of less than 3 MJ per kilogram.

Abstract: The present invention relates to a composition comprising (?) at least one inorganic binder and (?) at least one water-soluble copolymer based on (a) 0.1 to 20 wt % of at least one monomer of the formula (I) and (b) 25 to 99.9 wt % of at least one hydrophilic monomer (b) which is different from monomer (a), where the at least one copolymer has a molar mass average M of 1 500 000 to 30 000 000 g/mol. Furthermore, a process for producing this composition is disclosed. A further aspect of the present invention is the use of the copolymer of component (?) as rheological additive in a composition of the invention.

Abstract: The present invention relates to a composition comprising (?) at least one inorganic binder and (?) at least one water-soluble copolymer based on (a) 0.1 to 20 wt % of at least one monomer of the formula (I) and (b) 25 to 99.9 wt % of at least one hydrophilic monomer (b) which is different from monomer (a), where the at least one copolymer has a molar mass average M of 1 500 000 to 30 000 000 g/mol. Furthermore, a process for producing this composition is disclosed. A further aspect of the present invention is the use of the copolymer of component (?) as rheological additive in a composition of the invention.

Abstract: The invention relates to an insulated building wall comprising a composite thermal insulation system and an external building wall, where the composite thermal insulation system is affixed to the side of the building wall facing away from the building, the composite thermal insulation system comprising an at least two-layer thermal insulation cladding, with at least two layers each containing from 25 to 95% by weight of aerogel and from 0 to 75% by weight of inorganic fibres and from 0 to 70% by weight of inorganic fillers, wherein the layers of the thermal insulation cladding are joined to one another by means of an inorganic binder and the composite thermal insulation system has a gross calorific potential of less then 3 MJ per kilogram.

Abstract: The use of guanidinoacetic acid and/or salts thereof in combination with choline and/or betaine to produce an agent for improving brain function, bone growth and the mineralization of bones, for improving cartilage growth, for alleviating aging processes, for strengthening the immune system, as an antioxidative and neuroprotective agent, for lowering the cholesterol and triglyceride value, for preventing inflammatory processes and for lowering the blood sugar level in humans and vertebrates is described. In this connection it has surprisingly turned out that the new agents have a considerably higher bioavailability and are thus better taken up into the cells than was previously known when using creatine.

Abstract: The present invention relates to the use of guanidinoacetic acid and/or salts thereof as feed additive, in predominantly vegetarian diets, in particular use being made of salts with hydrochloric acid, hydrobromic acid and phosphoric acid. The use proceeds especially in individual doses from 0.01 to 100 g/kg of feed in the form of powders, granules, pastilles or capsules, the feed additive also being able to be used in combination with other physiologically active materials of value. The claimed use which is suitable especially for breeding and growing livestock, has recourse to a compound which is in particular stable in aqueous solution, can be converted to creatine under physiological conditions, and, in contrast to other guanidine derivatives, is completely available to physiological sectors of use.

Abstract: The present invention provides new addition compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, alpha-ketoglutaric acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid as well as in the form of sodium, potassium or calcium guanidinoacetate. These addition compounds have improved physiological and therapeutic properties and are particularly suitable for use as dietary supplements, as animal feeds and in cosmetic or dermatological preparations in which especially the marked stability and good bioavailability of the addition compounds come to the fore.

Abstract: The invention relates to a preparation comprising a creatine component, which has excellent bio-availability and leads to improved creatine retention in the human and animal body. The present invention further relates to a method for the production of said preparation, and to the use thereof as a nutritional supplement, functional food, animal feed additive, pharmaceutical, and as an additive for cosmetic and dermatologic formulations.

Abstract: The present invention relates to the use of guanidinoacetic acid and/or salts thereof as feed additive, in predominantly vegetarian diets, in particular use being made of salts with hydrochloric acid, hydrobromic acid and phosphoric acid. The use proceeds especially in individual doses from 0.01 to 100 g/kg of feed in the form of powders, granules, pastilles or capsules, the feed additive also being able to be used in combination with other physiologically active materials of value. The claimed use which is suitable especially for breeding and growing livestock, has recourse to a compound which is in particular stable in aqueous solution, can be converted to creatine under physiological conditions, and, in contrast to other guanidine derivatives, is completely available to physiological sectors of use.

Abstract: A new finished feed for domestic pets is proposed, containing at least one guanidinoacetic acid component as the active component with regard to nutritional physiology. The new finished feed which preferably has a water content of >8% by weight, can be produced in an extremely economical manner, wherein the main component has a significantly higher stability during passage through the gastrointestinal tract and is therefore only converted into creative under physiological conditions. For this reason the guanidinoacetic acid is also utilized to a high degree by the target group which is in particular cats and dogs.

Abstract: The present invention provides new addition compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, alpha-ketoglutaric acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid as well as in the form of sodium, potassium or calcium guanidinoacetate. These addition compounds have improved physiological and therapeutic properties and are particularly suitable for use as dietary supplements, as animal feeds and in cosmetic or dermatological preparations in which especially the marked stability and good bioavailability of the addition compounds come to the fore.

Abstract: A process for producing creatine, creatine monohydrate or guanidinoacetic acid is proposed, wherein firstly N-methylethanolamine or ethanolamine is catalytically dehydrogenated in each case in alkaline solution and the sarcosinate or glycinate solutions that are obtained in this manner are finally reacted under acidic conditions with a guanylating agent such as for example O-alkylisourea or cyanamide. In this manner products are obtained in high yields and very good purity where in contrast to the prior art no traces whatsoever of hydrocyanic acid, formaldehyde, chloroacetic acid or ammonia are present. The formation of the toxicologically critical dihydrotriazine is also avoided.

Abstract: The invention relates to a preparation comprising a creatine component, which has excellent bio-availability and leads to improved creatine retention in the human and animal body. The present invention further relates to a method for the production of said preparation, and to the use thereof as a nutritional supplement, functional food, animal feed additive, pharmaceutical, and as an additive for cosmetic and dermatologic formulations.

Abstract: The present invention provides new salts and/or addition compounds and/or complex compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, ?-ketoglutaric acid, oxalic acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, sulfuric acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid as well as in the form of sodium, potassium or calcium guanidinoacetate. These salts have improved physiological and therapeutic properties and are particularly suitable for use as dietary supplements, as animal feeds and in cosmetic or dermatological preparations in which especially the marked stability and good bioavailability of the salts come to the fore.

Abstract: The present invention relates to the use of guanidinoacetic acid and/or salts thereof as feed additive, in predominantly vegetarian diets, in particular use being made of salts with hydrochloric acid, hydrobromic acid and phosphoric acid. The use proceeds especially in individual doses from 0.01 to 100 g/kg of feed in the form of powders, granules, pastilles or capsules, the feed additive also being able to be used in combination with other physiologically active materials of value. The claimed use which is suitable especially for breeding and growing livestock, has recourse to a compound which is in particular stable in aqueous solution, can be converted to creatine under physiological conditions, and, in contrast to other guanidine derivatives, is completely available to physiological sectors of use.

Abstract: Physiological strengthening agents in the form of nutritional supplements, feed additives or in cosmetic preparations in the non-medicinal field of application, as well as plant stimulating agents is the use of guanidine compounds of the general formula (I) or their salts, especially creatinol, creatinol-O-phosphate or one of their salts with aspartic acid, ascorbic acid, succinic acid, fumaric acid, acetic acid or phosphoric acid. R1 and R2 can be organic or inorganic compounds, such as, phosphate, sulfate, acetyl, formyl, methyl, ethyl or propyl. The compounds are as nutritional supplements for, e.g., human being in the fields of education, sports, reconvalescence or geriatrics They can also be used as animal feed additives.

Abstract: A solid or aqueous alkaline preparation comprising a creatine component which comprises a buffer system which adjusts a pH of from 8.0 to 12.0 is described. The creatine is better protected with the aid of the buffer system from conversion into creatinine in the stomach. It has additionally emerged, surprisingly, that the novel formulations display a distinctly higher bioavailability and are thus taken up better by cells. Finally, the preparation of the invention has very good organoleptic properties, which in fact likewise could not be predicted. Owing to these particular advantages, the preparation of the invention is outstandingly suitable as dietary supplements, restoratives, medicinal products and feedstuffs.

Abstract: The use of guanidinoacetic acid and/or salts thereof in combination with choline and/or betaine to produce an agent for improving brain function, bone growth and the mineralization of bones, for improving cartilage growth, for alleviating aging processes, for strengthening the immune system, as an antioxidative and neuroprotective agent, for lowering the cholesterol and triglyceride value, for preventing inflammatory processes and for lowering the blood sugar level in humans and vertebrates is described. In this connection it has surprisingly turned out that the new agents have a considerably higher bioavailability and are thus better taken up into the cells than was previously known when using creatine.

Abstract: The present invention relates to a liquid formulation for human and animal nutrition, consisting of an aqueous solution, a guanidinoacetic acid component and at least one methyl group donor from the group of choline, methionine and betaine. In addition to the free guanidinoacetic acid, it is also possible to use salts, adducts and/or complexes as the guanidinoacetic acid component, which can additionally be combined with further physiologically active compounds. Since the guanidinoacetic acid component is present in dissolved form, formulations including those in the form of mineral water, lemonade, alcoholic drinks and drinking water formulations are envisaged. It has been found that, surprisingly, the guanidinoacetic acid component present in this liquid formulation has very good stability and is converted very rapidly to creatine in the body.

Abstract: A process for producing creatine, creatine monohydrate or guanidinoacetic acid is proposed, wherein firstly N-methylethanolamine or ethanolamine is catalytically dehydrogenated in each case in alkaline solution and the sarcosinate or glycinate solutions that are obtained in this manner are finally reacted under acidic conditions with a guanylating agent such as for example O-alkylisourea or cyanamide. In this manner products are obtained in high yields and very good purity where in contrast to the prior art no traces whatsoever of hydrocyanic acid, formaldehyde, chloroacetic acid or ammonia are present. The formation of the toxicologically critical dihydrotriazine is also avoided.